Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
Interim boss Jack Dorsey said the micro-blogging site isn’t satisfied with just a 66 pct increase in Q2 revenue. His prescription for what ails Twitter, however, is cryptic. Companies that can’t express goals clearly, especially ones seeking a CEO, reduce chances for success.
Patrick Soon-Shiong, whose NantKwest just fetched a $3.4 bln value, has made minority investors rich before but also treated them poorly. His new cancer treatment lacks supportive data for such a difficult task amid stiff competition. In this market, though, almost anything goes.
The pharma giant has since 2012 racked up over $100 bln in deals and changed its name twice and its tax HQ once. Selling its once core business to Teva for $41 bln leaves Allergan free to pursue even bigger targets. But too much reliance on M&A could leave the Petri dish exposed.
- Breakdown: Watchdogs chew on health insurer deals
- Amazon rides cloud to value bigger than Wal-Mart
- Anthem and Cigna may have a price but not a deal
- U.S. medical device firms hop Obamacare deal train
- Apple has time on its side
- Google's new CFO recalibrates investment algorithm
- Biotech feeds on itself with $7 bln Celgene deal